Free tool
FAERS Monitor: Varibar Honey
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208143 or its brand name (Varibar Honey, Barium Sulfate). Reports on generic versions are filed under their own applications.
Reports
353
Serious
212
60% of reports
Hospitalization
123
Death reported
31
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- urticaria27
- diarrhoea26
- pruritus19
- acute kidney injury18
- dyspnoea18
- renal failure18
- no adverse event16
- vomiting16
- chronic kidney disease15
- rash15
- abdominal pain13
- nausea13
- drug hypersensitivity12
- fatigue12
- aspiration11
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 2 |
| 2006 | 3 |
| 2007 | 3 |
| 2008 | 21 |
| 2009 | 6 |
| 2010 | 10 |
| 2011 | 13 |
| 2012 | 12 |
| 2013 | 17 |
| 2014 | 13 |
| 2015 | 9 |
| 2016 | 20 |
| 2017 | 28 |
| 2018 | 27 |
| 2019 | 27 |
| 2020 | 18 |
| 2021 | 27 |
| 2022 | 32 |
| 2023 | 23 |
| 2024 | 12 |
| 2025 | 17 |
| 2026 | 13 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,806 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| aspirationSignal | 11 | 59.9 | 33.5 | 579 |
| chronic kidney diseaseSignal | 15 | 11.8 | 7.2 | 138 |
| urticariaSignal | 27 | 9.6 | 6.7 | 201 |
| renal failureSignal | 18 | 8.1 | 5.1 | 105 |
| acute kidney injurySignal | 18 | 7.0 | 4.5 | 87 |
| no adverse eventSignal | 16 | 5.3 | 3.3 | 51 |
| drug hypersensitivitySignal | 12 | 3.7 | 2.1 | 21 |
| abdominal painSignal | 13 | 3.3 | 2.0 | 19 |
| pruritusSignal | 19 | 2.9 | 1.9 | 23 |
| diarrhoeaSignal | 26 | 2.4 | 1.7 | 20 |
| rashSignal | 15 | 2.1 | 1.2 | 7 |
| vomitingSignal | 16 | 2.0 | 1.3 | 8 |
| dyspnoea | 18 | 1.9 | 1.2 | 7 |
| nausea | 13 | 1.0 | 0.6 | 0 |
| fatigue | 12 | 0.9 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.